Publication | Open Access

Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial

VaccinationCross-protectionVaccine DevelopmentVaccine SurveillanceImmunologyTherapeutic VaccineInterim ResultsVaccine DesignMedicineCovid-19